Cargando…

Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width

The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC reduced the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Kyoko, Yokoyama, Keitaro, Nakayama, Masaaki, Fukagawa, Masafumi, Hirakata, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844010/
https://www.ncbi.nlm.nih.gov/pubmed/35165297
http://dx.doi.org/10.1038/s41598-022-06261-0
_version_ 1784651391275368448
author Ito, Kyoko
Yokoyama, Keitaro
Nakayama, Masaaki
Fukagawa, Masafumi
Hirakata, Hideki
author_facet Ito, Kyoko
Yokoyama, Keitaro
Nakayama, Masaaki
Fukagawa, Masafumi
Hirakata, Hideki
author_sort Ito, Kyoko
collection PubMed
description The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC reduced the doses of ESAs and intravenous iron without affecting haemoglobin (Hb); however, the cost-effectiveness of FC was unclear. We retrospectively implemented a cost-effectiveness analysis comparing the incremental cost-effectiveness ratios (ICERs) in FC (n = 42) and control (n = 40) groups in patients with serum phosphate and Hb controlled within the ranges of 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Costs included drug costs of phosphate binders, ESAs, and intravenous iron. Elevated red cell distribution width (RDW) has been reported to be associated with mortality in HD patients and was therefore used as an effectiveness index. The mean (95% confidence interval) differences in drug costs and RDW between the FC and control groups were US$ − 421.36 (− 778.94 to − 63.78, p = 0.02) and − 0.83% (− 1.61 to – 0.05, p = 0.04), respectively. ICER indicated a decrease of US$ 507.66 per 1% decrease in RDW. FC was more cost-effective than non-iron-based phosphate binders. Iron absorbed via FC could promote erythropoiesis and contribute to renal anaemia treatment.
format Online
Article
Text
id pubmed-8844010
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88440102022-02-16 Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width Ito, Kyoko Yokoyama, Keitaro Nakayama, Masaaki Fukagawa, Masafumi Hirakata, Hideki Sci Rep Article The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis-stimulating agents (ESAs). In that study, FC reduced the doses of ESAs and intravenous iron without affecting haemoglobin (Hb); however, the cost-effectiveness of FC was unclear. We retrospectively implemented a cost-effectiveness analysis comparing the incremental cost-effectiveness ratios (ICERs) in FC (n = 42) and control (n = 40) groups in patients with serum phosphate and Hb controlled within the ranges of 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Costs included drug costs of phosphate binders, ESAs, and intravenous iron. Elevated red cell distribution width (RDW) has been reported to be associated with mortality in HD patients and was therefore used as an effectiveness index. The mean (95% confidence interval) differences in drug costs and RDW between the FC and control groups were US$ − 421.36 (− 778.94 to − 63.78, p = 0.02) and − 0.83% (− 1.61 to – 0.05, p = 0.04), respectively. ICER indicated a decrease of US$ 507.66 per 1% decrease in RDW. FC was more cost-effective than non-iron-based phosphate binders. Iron absorbed via FC could promote erythropoiesis and contribute to renal anaemia treatment. Nature Publishing Group UK 2022-02-14 /pmc/articles/PMC8844010/ /pubmed/35165297 http://dx.doi.org/10.1038/s41598-022-06261-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ito, Kyoko
Yokoyama, Keitaro
Nakayama, Masaaki
Fukagawa, Masafumi
Hirakata, Hideki
Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title_full Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title_fullStr Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title_full_unstemmed Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title_short Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
title_sort ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844010/
https://www.ncbi.nlm.nih.gov/pubmed/35165297
http://dx.doi.org/10.1038/s41598-022-06261-0
work_keys_str_mv AT itokyoko ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth
AT yokoyamakeitaro ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth
AT nakayamamasaaki ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth
AT fukagawamasafumi ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth
AT hirakatahideki ferriccitratehydrateisassociatedwithareducedcostofdrugsandasmallerchangeinredbloodcelldistributionwidth